Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi

Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s disease med appears to be moving slower than expected.